Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

DFT383 hos pediatriske deltakere med nefropatisk cystinose (CYStem)

15. oktober 2026 oppdatert av: Novartis Pharmaceuticals

En åpen, multisenter, fase I/II-studie for å vurdere sikkerhet, toleranse og effekt av DFT383 hos pediatriske deltakere med nefropatisk cystinose

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.

The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.

This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.

The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.

Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.

The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.

Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.

Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

    • Arizona
      • Phoenix, Arizona, Forente stater, 85016
        • Rekruttering
        • Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Shanna White
    • California
      • San Diego, California, Forente stater, 92123
        • Rekruttering
        • University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nadine Benador nbenador@health.ucsd.edu
      • Stanford, California, Forente stater, 94305
        • Rekruttering
        • Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
        • Hovedetterforsker:
          • Alice Bertaina
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
        • Hovedetterforsker:
          • Laurence (Larry) Greenbaum
        • Ta kontakt med:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia (Recruiting Cohort 0)
        • Ta kontakt med:
          • Melissa Cadnapaphornchai
          • Telefonnummer: 215-590-2449
        • Hovedetterforsker:
          • Melissa Cadnapaphornchai
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ewa Elenberg

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 5 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all the following criteria:

  1. Informed consent in writing from parent(s) or legal guardian(s) must be provided
  2. 2 to 5 years of age (including 5 years and 364 days old) at Screening
  3. Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
  4. Oral cysteamine therapy for at least 6 months
  5. Historic clinical diagnosis of nephropathic cystinosis
  6. Laboratory evidence of of renal fanconi syndrome (RFS)
  7. Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
  8. Received all age-appropriate vaccinations

Key exclusion Criteria for Cohort 1 and 0

  1. A history of kidney transplantation
  2. A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
  3. History of malignancy
  4. A severe or uncontrolled medical disorder
  5. Major surgery within 90 days

Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:

1. Indomethacin within 2 weeks prior to Screening

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cohort 1 (DFT383)

Treatment with DFT383

DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.

Ingen inngripen: Cohort 0 (SoC)

No study treatment, will continue with standard of care (cysteamine).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Core Phase - Incidence of adverse events (Cohort 1)
Tidsramme: Up to 32 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 32 months
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Tidsramme: 42 days post DFT infusion

Hematological reconstitution by Day 42 post-DFT383 infusion

42 days post DFT infusion
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Tidsramme: Up to 32 months

Proportion of participants with reversal of renal Fanconi syndrome (RFS)

Up to 32 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Core Phase - Number of participants independent from cysteamine
Tidsramme: up to 24 months

Independence from oral and ophthalmic cysteamine

up to 24 months
Core Phase - Health-related quality of life (HRQOL)
Tidsramme: Up to 32 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 32 months
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Tidsramme: Up to 24 months

Time from infusion to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Tidsramme: Up to 24 months

Time from screening to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Duration of reversal of RFS
Tidsramme: Up to 24 months

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Tidsramme: Up to 27 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 27 months
Core Phase - Change from baseline on urine amino acids
Tidsramme: Up to 27 months

Change from baseline on urine amino acids

Up to 27 months
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Tidsramme: Up to 27 months

Change from baseline on urinary glucose to creatinine ratio

Up to 27 months
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Tidsramme: Up to 27 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 27 months
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Tidsramme: Up to 27 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 27 months
Core Phase - Number of participants with improvement of proximal tubular function
Tidsramme: Up to 27 months

Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization.

Up to 27 months
Core Phase - Corneal cystine crystal content
Tidsramme: Up to 27 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 27 months
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Tidsramme: Up to 27 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 27 months
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Tidsramme: Up to 27 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 27 months
Core Phase - Number of participants with malignancy (Cohort 1)
Tidsramme: Up to 27 months

Number of participants with malignancy

Up to 27 months
Core Phase - Time to hematological reconstitution (Cohort 1)
Tidsramme: Up to 24 months

Time to hematological reconstitution

Up to 24 months
Core Phase - Time to platelet engraftment (Cohort 1)
Tidsramme: Up to 24 months

Time to platelet engraftment

Up to 24 months
Core Phase - Incidence of Adverse Events (Cohort 0)
Tidsramme: up to 24 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

up to 24 months
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Tidsramme: Up to 15 years and 8 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 15 years and 8 months
Extension Phase - Number of participants with malignancy (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Number of participants with malignancy

Up to 15 years and 3 months
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 15 years and 3 months
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Change from baseline on urine amino acids

Up to 15 years and 3 months
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Change from baseline on urinary glucose to creatinine ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 15 years and 3 months
Extension Phase - Duration of reversal of RFS (Cohort 1)
Tidsramme: Up to 15 years

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 15 years
Extension Phase - Number of participants with kidney failure (Cohort 1)
Tidsramme: Up to 15 years

Number of participants with kidney failure

Up to 15 years
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Tidsramme: Up to 15 years

Independence from oral and ophthalmic cysteamine

Up to 15 years
Extension Phase - Corneal cystine crystal content (Cohort 1)
Tidsramme: Up to 15 years and 3 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 15 years and 3 months
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Tidsramme: Up to 15 years and 8 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 15 years and 8 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juni 2025

Primær fullføring (Antatt)

28. mai 2031

Studiet fullført (Antatt)

28. mai 2044

Datoer for studieregistrering

Først innsendt

17. mars 2025

Først innsendt som oppfylte QC-kriteriene

27. mars 2025

Først lagt ut (Faktiske)

4. april 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere